Abstract
The importance of tumour angiogenesis in the process of tumour growth and progression in solid tumours has been widely accepted. Among many angiogenic factors, vascular endothelial growth factor (VEGF) has been shown to play a major role in the development and dissemination of the malignant tumours. Nitric oxide (NO) production was also observed in solid tumour tissues. NO has been reported to play an important role for the mitogenic effect of VEGF in the angiogenic process. However, little is known about the correlation between VEGF and NO in circulating levels. Therefore, we investigated serum VEGF and NO concentrations in human gastric cancers as well as healthy individuals, and examined the influence of tumour stage on circulating level of VEGF. The study consisted of 11 healthy individuals and 37 patients with primary gastric cancer who did not receive any prior therapy. Patients were categorized into four groups according to TNM classification. The level of VEGF165 in preoperative sera of gastric cancer patients and healthy donors was assayed using the quantitative sandwich enzyme immunoassay technique. NO concentration was estimated indirectly from serum nitrite. The ANOVA test showed a significant difference in serum VEGF165 concentrations between tumour stages (P < 0.001). A striking relationship was found between serum NO levels and tumour stage (P < 0.001). A significant difference was also seen between healthy individuals and patients with stage 1 disease. The present study suggested that large tumour burden was associated with significantly increased levels of VEGF165 and NO. © 1999 Cancer Research Campaign
Keywords: gastric cancer, nitric oxide, VEGF, serum
Full Text
The Full Text of this article is available as a PDF (81.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andrade S. P., Hart I. R., Piper P. J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol. 1992 Dec;107(4):1092–1095. doi: 10.1111/j.1476-5381.1992.tb13412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Araya M., Terashima M., Takagane A., Abe K., Nishizuka S., Yonezawa H., Irinoda T., Nakaya T., Saito K. Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol. 1997 Aug;65(4):232–236. doi: 10.1002/(sici)1096-9098(199708)65:4<232::aid-jso2>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Cobbs C. S., Brenman J. E., Aldape K. D., Bredt D. S., Israel M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995 Feb 15;55(4):727–730. [PubMed] [Google Scholar]
- Dong Z., Staroselsky A. H., Qi X., Xie K., Fidler I. J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 1994 Feb 1;54(3):789–793. [PubMed] [Google Scholar]
- Fidler I. J., Ellis L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994 Oct 21;79(2):185–188. doi: 10.1016/0092-8674(94)90187-2. [DOI] [PubMed] [Google Scholar]
- Fukumura D., Yuan F., Endo M., Jain R. K. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol. 1997 Feb;150(2):713–725. [PMC free article] [PubMed] [Google Scholar]
- Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W. A., Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998 Apr 15;90(8):587–596. doi: 10.1093/jnci/90.8.587. [DOI] [PubMed] [Google Scholar]
- Hevel J. M., Marletta M. A. Nitric-oxide synthase assays. Methods Enzymol. 1994;233:250–258. doi: 10.1016/s0076-6879(94)33028-x. [DOI] [PubMed] [Google Scholar]
- Jenkins D. C., Charles I. G., Thomsen L. L., Moss D. W., Holmes L. S., Baylis S. A., Rhodes P., Westmore K., Emson P. C., Moncada S. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4392–4396. doi: 10.1073/pnas.92.10.4392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maeda K., Chung Y. S., Ogawa Y., Takatsuka S., Kang S. M., Ogawa M., Sawada T., Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996 Mar 1;77(5):858–863. doi: 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
- Maeda K., Chung Y. S., Takatsuka S., Ogawa Y., Onoda N., Sawada T., Kato Y., Nitta A., Arimoto Y., Kondo Y. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 1995 Aug;72(2):319–323. doi: 10.1038/bjc.1995.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
- Moriyama A., Masumoto A., Nanri H., Tabaru A., Unoki H., Imoto I., Ikeda M., Otsuki M. High plasma concentrations of nitrite/nitrate in patients with hepatocellular carcinoma. Am J Gastroenterol. 1997 Sep;92(9):1520–1523. [PubMed] [Google Scholar]
- Nathan C., Xie Q. W. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994 Sep 23;78(6):915–918. doi: 10.1016/0092-8674(94)90266-6. [DOI] [PubMed] [Google Scholar]
- Pipili-Synetos E., Sakkoula E., Maragoudakis M. E. Nitric oxide is involved in the regulation of angiogenesis. Br J Pharmacol. 1993 Apr;108(4):855–857. doi: 10.1111/j.1476-5381.1993.tb13476.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Privat C., Lantoine F., Bedioui F., Millanvoye van Brussel E., Devynck J., Devynck M. A. Nitric oxide production by endothelial cells: comparison of three methods of quantification. Life Sci. 1997;61(12):1193–1202. doi: 10.1016/s0024-3205(97)00661-9. [DOI] [PubMed] [Google Scholar]
- Senger D. R., Van de Water L., Brown L. F., Nagy J. A., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Dvorak A. M., Dvorak H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993 Sep;12(3-4):303–324. doi: 10.1007/BF00665960. [DOI] [PubMed] [Google Scholar]
- Thomsen L. L., Lawton F. G., Knowles R. G., Beesley J. E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994 Mar 1;54(5):1352–1354. [PubMed] [Google Scholar]
- Thomsen L. L., Miles D. W., Happerfield L., Bobrow L. G., Knowles R. G., Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995 Jul;72(1):41–44. doi: 10.1038/bjc.1995.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thomsen L. L., Scott J. M., Topley P., Knowles R. G., Keerie A. J., Frend A. J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 1997 Aug 1;57(15):3300–3304. [PubMed] [Google Scholar]
- Yamamoto Y., Toi M., Kondo S., Matsumoto T., Suzuki H., Kitamura M., Tsuruta K., Taniguchi T., Okamoto A., Mori T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res. 1996 May;2(5):821–826. [PubMed] [Google Scholar]